Global Solid Tumor Drug Market Growth 2023-2029

February 2023 | 107 pages | ID: G28E14714F23EN
LP Information

Abstracts

The report requires updating with new data and is sent in 48 hours after order is placed.

LPI (LP Information)' newest research report, the “Solid Tumor Drug Industry Forecast” looks at past sales and reviews total world Solid Tumor Drug sales in 2022, providing a comprehensive analysis by region and market sector of projected Solid Tumor Drug sales for 2023 through 2029. With Solid Tumor Drug sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Solid Tumor Drug industry.

This Insight Report provides a comprehensive analysis of the global Solid Tumor Drug landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Solid Tumor Drug portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Solid Tumor Drug market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Solid Tumor Drug and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Solid Tumor Drug.

The global Solid Tumor Drug market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.

United States market for Solid Tumor Drug is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

China market for Solid Tumor Drug is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

Europe market for Solid Tumor Drug is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

Global key Solid Tumor Drug players cover AstraZeneca, Biogen, Baxter, Celgene Corporation, Abbott Laboratories, Pfizer Inc, Amgen Limited & Amgen Ireland Limited, Bristol-Myers Squibb Company and GlaxoSmithKline plc., etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.

This report presents a comprehensive overview, market shares, and growth opportunities of Solid Tumor Drug market by product type, application, key manufacturers and key regions and countries.

Market Segmentation:

Segmentation by type

• Small Molecules
• Biologics

Segmentation by application

• Oncology
• Neurology
• Radiology
• Others

This report also splits the market by region:

• Americas
• United States
• Canada
• Mexico
• Brazil
• APAC
• China
• Japan
• Korea
• Southeast Asia
• India
• Australia
• Europe
• Germany
• France
• UK
• Italy
• Russia
• Middle East & Africa
• Egypt
• South Africa
• Israel
• Turkey
• GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.

• AstraZeneca
• Biogen
• Baxter
• Celgene Corporation
• Abbott Laboratories
• Pfizer Inc
• Amgen Limited & Amgen Ireland Limited
• Bristol-Myers Squibb Company
• GlaxoSmithKline plc.
• F. Hoffmann-La Roche Ltd.
• Eli Lilly and Company
• Johnson & Johnson

Key Questions Addressed in this Report

What is the 10-year outlook for the global Solid Tumor Drug market?

What factors are driving Solid Tumor Drug market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Solid Tumor Drug market opportunities vary by end market size?

How does Solid Tumor Drug break out type, application?

What are the influences of COVID-19 and Russia-Ukraine war?

Contents

1 SCOPE OF THE REPORT

1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats

2 EXECUTIVE SUMMARY

2.1 World Market Overview
  2.1.1 Global Solid Tumor Drug Annual Sales 2018-2029
  2.1.2 World Current & Future Analysis for Solid Tumor Drug by Geographic Region, 2018, 2022 & 2029
  2.1.3 World Current & Future Analysis for Solid Tumor Drug by Country/Region, 2018, 2022 & 2029
2.2 Solid Tumor Drug Segment by Type
  2.2.1 Small Molecules
  2.2.2 Biologics
2.3 Solid Tumor Drug Sales by Type
  2.3.1 Global Solid Tumor Drug Sales Market Share by Type (2018-2023)
  2.3.2 Global Solid Tumor Drug Revenue and Market Share by Type (2018-2023)
  2.3.3 Global Solid Tumor Drug Sale Price by Type (2018-2023)
2.4 Solid Tumor Drug Segment by Application
  2.4.1 Oncology
  2.4.2 Neurology
  2.4.3 Radiology
  2.4.4 Others
2.5 Solid Tumor Drug Sales by Application
  2.5.1 Global Solid Tumor Drug Sale Market Share by Application (2018-2023)
  2.5.2 Global Solid Tumor Drug Revenue and Market Share by Application (2018-2023)
  2.5.3 Global Solid Tumor Drug Sale Price by Application (2018-2023)

3 GLOBAL SOLID TUMOR DRUG BY COMPANY

3.1 Global Solid Tumor Drug Breakdown Data by Company
  3.1.1 Global Solid Tumor Drug Annual Sales by Company (2018-2023)
  3.1.2 Global Solid Tumor Drug Sales Market Share by Company (2018-2023)
3.2 Global Solid Tumor Drug Annual Revenue by Company (2018-2023)
  3.2.1 Global Solid Tumor Drug Revenue by Company (2018-2023)
  3.2.2 Global Solid Tumor Drug Revenue Market Share by Company (2018-2023)
3.3 Global Solid Tumor Drug Sale Price by Company
3.4 Key Manufacturers Solid Tumor Drug Producing Area Distribution, Sales Area, Product Type
  3.4.1 Key Manufacturers Solid Tumor Drug Product Location Distribution
  3.4.2 Players Solid Tumor Drug Products Offered
3.5 Market Concentration Rate Analysis
  3.5.1 Competition Landscape Analysis
  3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion

4 WORLD HISTORIC REVIEW FOR SOLID TUMOR DRUG BY GEOGRAPHIC REGION

4.1 World Historic Solid Tumor Drug Market Size by Geographic Region (2018-2023)
  4.1.1 Global Solid Tumor Drug Annual Sales by Geographic Region (2018-2023)
  4.1.2 Global Solid Tumor Drug Annual Revenue by Geographic Region (2018-2023)
4.2 World Historic Solid Tumor Drug Market Size by Country/Region (2018-2023)
  4.2.1 Global Solid Tumor Drug Annual Sales by Country/Region (2018-2023)
  4.2.2 Global Solid Tumor Drug Annual Revenue by Country/Region (2018-2023)
4.3 Americas Solid Tumor Drug Sales Growth
4.4 APAC Solid Tumor Drug Sales Growth
4.5 Europe Solid Tumor Drug Sales Growth
4.6 Middle East & Africa Solid Tumor Drug Sales Growth

5 AMERICAS

5.1 Americas Solid Tumor Drug Sales by Country
  5.1.1 Americas Solid Tumor Drug Sales by Country (2018-2023)
  5.1.2 Americas Solid Tumor Drug Revenue by Country (2018-2023)
5.2 Americas Solid Tumor Drug Sales by Type
5.3 Americas Solid Tumor Drug Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil

6 APAC

6.1 APAC Solid Tumor Drug Sales by Region
  6.1.1 APAC Solid Tumor Drug Sales by Region (2018-2023)
  6.1.2 APAC Solid Tumor Drug Revenue by Region (2018-2023)
6.2 APAC Solid Tumor Drug Sales by Type
6.3 APAC Solid Tumor Drug Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan

7 EUROPE

7.1 Europe Solid Tumor Drug by Country
  7.1.1 Europe Solid Tumor Drug Sales by Country (2018-2023)
  7.1.2 Europe Solid Tumor Drug Revenue by Country (2018-2023)
7.2 Europe Solid Tumor Drug Sales by Type
7.3 Europe Solid Tumor Drug Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia

8 MIDDLE EAST & AFRICA

8.1 Middle East & Africa Solid Tumor Drug by Country
  8.1.1 Middle East & Africa Solid Tumor Drug Sales by Country (2018-2023)
  8.1.2 Middle East & Africa Solid Tumor Drug Revenue by Country (2018-2023)
8.2 Middle East & Africa Solid Tumor Drug Sales by Type
8.3 Middle East & Africa Solid Tumor Drug Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries

9 MARKET DRIVERS, CHALLENGES AND TRENDS

9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends

10 MANUFACTURING COST STRUCTURE ANALYSIS

10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Solid Tumor Drug
10.3 Manufacturing Process Analysis of Solid Tumor Drug
10.4 Industry Chain Structure of Solid Tumor Drug

11 MARKETING, DISTRIBUTORS AND CUSTOMER

11.1 Sales Channel
  11.1.1 Direct Channels
  11.1.2 Indirect Channels
11.2 Solid Tumor Drug Distributors
11.3 Solid Tumor Drug Customer

12 WORLD FORECAST REVIEW FOR SOLID TUMOR DRUG BY GEOGRAPHIC REGION

12.1 Global Solid Tumor Drug Market Size Forecast by Region
  12.1.1 Global Solid Tumor Drug Forecast by Region (2024-2029)
  12.1.2 Global Solid Tumor Drug Annual Revenue Forecast by Region (2024-2029)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Solid Tumor Drug Forecast by Type
12.7 Global Solid Tumor Drug Forecast by Application

13 KEY PLAYERS ANALYSIS

13.1 AstraZeneca
  13.1.1 AstraZeneca Company Information
  13.1.2 AstraZeneca Solid Tumor Drug Product Portfolios and Specifications
  13.1.3 AstraZeneca Solid Tumor Drug Sales, Revenue, Price and Gross Margin (2018-2023)
  13.1.4 AstraZeneca Main Business Overview
  13.1.5 AstraZeneca Latest Developments
13.2 Biogen
  13.2.1 Biogen Company Information
  13.2.2 Biogen Solid Tumor Drug Product Portfolios and Specifications
  13.2.3 Biogen Solid Tumor Drug Sales, Revenue, Price and Gross Margin (2018-2023)
  13.2.4 Biogen Main Business Overview
  13.2.5 Biogen Latest Developments
13.3 Baxter
  13.3.1 Baxter Company Information
  13.3.2 Baxter Solid Tumor Drug Product Portfolios and Specifications
  13.3.3 Baxter Solid Tumor Drug Sales, Revenue, Price and Gross Margin (2018-2023)
  13.3.4 Baxter Main Business Overview
  13.3.5 Baxter Latest Developments
13.4 Celgene Corporation
  13.4.1 Celgene Corporation Company Information
  13.4.2 Celgene Corporation Solid Tumor Drug Product Portfolios and Specifications
  13.4.3 Celgene Corporation Solid Tumor Drug Sales, Revenue, Price and Gross Margin (2018-2023)
  13.4.4 Celgene Corporation Main Business Overview
  13.4.5 Celgene Corporation Latest Developments
13.5 Abbott Laboratories
  13.5.1 Abbott Laboratories Company Information
  13.5.2 Abbott Laboratories Solid Tumor Drug Product Portfolios and Specifications
  13.5.3 Abbott Laboratories Solid Tumor Drug Sales, Revenue, Price and Gross Margin (2018-2023)
  13.5.4 Abbott Laboratories Main Business Overview
  13.5.5 Abbott Laboratories Latest Developments
13.6 Pfizer Inc
  13.6.1 Pfizer Inc Company Information
  13.6.2 Pfizer Inc Solid Tumor Drug Product Portfolios and Specifications
  13.6.3 Pfizer Inc Solid Tumor Drug Sales, Revenue, Price and Gross Margin (2018-2023)
  13.6.4 Pfizer Inc Main Business Overview
  13.6.5 Pfizer Inc Latest Developments
13.7 Amgen Limited & Amgen Ireland Limited
  13.7.1 Amgen Limited & Amgen Ireland Limited Company Information
  13.7.2 Amgen Limited & Amgen Ireland Limited Solid Tumor Drug Product Portfolios and Specifications
  13.7.3 Amgen Limited & Amgen Ireland Limited Solid Tumor Drug Sales, Revenue, Price and Gross Margin (2018-2023)
  13.7.4 Amgen Limited & Amgen Ireland Limited Main Business Overview
  13.7.5 Amgen Limited & Amgen Ireland Limited Latest Developments
13.8 Bristol-Myers Squibb Company
  13.8.1 Bristol-Myers Squibb Company Company Information
  13.8.2 Bristol-Myers Squibb Company Solid Tumor Drug Product Portfolios and Specifications
  13.8.3 Bristol-Myers Squibb Company Solid Tumor Drug Sales, Revenue, Price and Gross Margin (2018-2023)
  13.8.4 Bristol-Myers Squibb Company Main Business Overview
  13.8.5 Bristol-Myers Squibb Company Latest Developments
13.9 GlaxoSmithKline plc.
  13.9.1 GlaxoSmithKline plc. Company Information
  13.9.2 GlaxoSmithKline plc. Solid Tumor Drug Product Portfolios and Specifications
  13.9.3 GlaxoSmithKline plc. Solid Tumor Drug Sales, Revenue, Price and Gross Margin (2018-2023)
  13.9.4 GlaxoSmithKline plc. Main Business Overview
  13.9.5 GlaxoSmithKline plc. Latest Developments
13.10 F. Hoffmann-La Roche Ltd.
  13.10.1 F. Hoffmann-La Roche Ltd. Company Information
  13.10.2 F. Hoffmann-La Roche Ltd. Solid Tumor Drug Product Portfolios and Specifications
  13.10.3 F. Hoffmann-La Roche Ltd. Solid Tumor Drug Sales, Revenue, Price and Gross Margin (2018-2023)
  13.10.4 F. Hoffmann-La Roche Ltd. Main Business Overview
  13.10.5 F. Hoffmann-La Roche Ltd. Latest Developments
13.11 Eli Lilly and Company
  13.11.1 Eli Lilly and Company Company Information
  13.11.2 Eli Lilly and Company Solid Tumor Drug Product Portfolios and Specifications
  13.11.3 Eli Lilly and Company Solid Tumor Drug Sales, Revenue, Price and Gross Margin (2018-2023)
  13.11.4 Eli Lilly and Company Main Business Overview
  13.11.5 Eli Lilly and Company Latest Developments
13.12 Johnson & Johnson
  13.12.1 Johnson & Johnson Company Information
  13.12.2 Johnson & Johnson Solid Tumor Drug Product Portfolios and Specifications
  13.12.3 Johnson & Johnson Solid Tumor Drug Sales, Revenue, Price and Gross Margin (2018-2023)
  13.12.4 Johnson & Johnson Main Business Overview
  13.12.5 Johnson & Johnson Latest Developments

14 RESEARCH FINDINGS AND CONCLUSION

List Of Tables

LIST OF TABLES

Table 1. Solid Tumor Drug Annual Sales CAGR by Geographic Region (2018, 2022 & 2029) & ($ millions)
Table 2. Solid Tumor Drug Annual Sales CAGR by Country/Region (2018, 2022 & 2029) & ($ millions)
Table 3. Major Players of Small Molecules
Table 4. Major Players of Biologics
Table 5. Global Solid Tumor Drug Sales by Type (2018-2023) & (K MT)
Table 6. Global Solid Tumor Drug Sales Market Share by Type (2018-2023)
Table 7. Global Solid Tumor Drug Revenue by Type (2018-2023) & ($ million)
Table 8. Global Solid Tumor Drug Revenue Market Share by Type (2018-2023)
Table 9. Global Solid Tumor Drug Sale Price by Type (2018-2023) & (USD/MT)
Table 10. Global Solid Tumor Drug Sales by Application (2018-2023) & (K MT)
Table 11. Global Solid Tumor Drug Sales Market Share by Application (2018-2023)
Table 12. Global Solid Tumor Drug Revenue by Application (2018-2023)
Table 13. Global Solid Tumor Drug Revenue Market Share by Application (2018-2023)
Table 14. Global Solid Tumor Drug Sale Price by Application (2018-2023) & (USD/MT)
Table 15. Global Solid Tumor Drug Sales by Company (2018-2023) & (K MT)
Table 16. Global Solid Tumor Drug Sales Market Share by Company (2018-2023)
Table 17. Global Solid Tumor Drug Revenue by Company (2018-2023) ($ Millions)
Table 18. Global Solid Tumor Drug Revenue Market Share by Company (2018-2023)
Table 19. Global Solid Tumor Drug Sale Price by Company (2018-2023) & (USD/MT)
Table 20. Key Manufacturers Solid Tumor Drug Producing Area Distribution and Sales Area
Table 21. Players Solid Tumor Drug Products Offered
Table 22. Solid Tumor Drug Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
Table 23. New Products and Potential Entrants
Table 24. Mergers & Acquisitions, Expansion
Table 25. Global Solid Tumor Drug Sales by Geographic Region (2018-2023) & (K MT)
Table 26. Global Solid Tumor Drug Sales Market Share Geographic Region (2018-2023)
Table 27. Global Solid Tumor Drug Revenue by Geographic Region (2018-2023) & ($ millions)
Table 28. Global Solid Tumor Drug Revenue Market Share by Geographic Region (2018-2023)
Table 29. Global Solid Tumor Drug Sales by Country/Region (2018-2023) & (K MT)
Table 30. Global Solid Tumor Drug Sales Market Share by Country/Region (2018-2023)
Table 31. Global Solid Tumor Drug Revenue by Country/Region (2018-2023) & ($ millions)
Table 32. Global Solid Tumor Drug Revenue Market Share by Country/Region (2018-2023)
Table 33. Americas Solid Tumor Drug Sales by Country (2018-2023) & (K MT)
Table 34. Americas Solid Tumor Drug Sales Market Share by Country (2018-2023)
Table 35. Americas Solid Tumor Drug Revenue by Country (2018-2023) & ($ Millions)
Table 36. Americas Solid Tumor Drug Revenue Market Share by Country (2018-2023)
Table 37. Americas Solid Tumor Drug Sales by Type (2018-2023) & (K MT)
Table 38. Americas Solid Tumor Drug Sales by Application (2018-2023) & (K MT)
Table 39. APAC Solid Tumor Drug Sales by Region (2018-2023) & (K MT)
Table 40. APAC Solid Tumor Drug Sales Market Share by Region (2018-2023)
Table 41. APAC Solid Tumor Drug Revenue by Region (2018-2023) & ($ Millions)
Table 42. APAC Solid Tumor Drug Revenue Market Share by Region (2018-2023)
Table 43. APAC Solid Tumor Drug Sales by Type (2018-2023) & (K MT)
Table 44. APAC Solid Tumor Drug Sales by Application (2018-2023) & (K MT)
Table 45. Europe Solid Tumor Drug Sales by Country (2018-2023) & (K MT)
Table 46. Europe Solid Tumor Drug Sales Market Share by Country (2018-2023)
Table 47. Europe Solid Tumor Drug Revenue by Country (2018-2023) & ($ Millions)
Table 48. Europe Solid Tumor Drug Revenue Market Share by Country (2018-2023)
Table 49. Europe Solid Tumor Drug Sales by Type (2018-2023) & (K MT)
Table 50. Europe Solid Tumor Drug Sales by Application (2018-2023) & (K MT)
Table 51. Middle East & Africa Solid Tumor Drug Sales by Country (2018-2023) & (K MT)
Table 52. Middle East & Africa Solid Tumor Drug Sales Market Share by Country (2018-2023)
Table 53. Middle East & Africa Solid Tumor Drug Revenue by Country (2018-2023) & ($ Millions)
Table 54. Middle East & Africa Solid Tumor Drug Revenue Market Share by Country (2018-2023)
Table 55. Middle East & Africa Solid Tumor Drug Sales by Type (2018-2023) & (K MT)
Table 56. Middle East & Africa Solid Tumor Drug Sales by Application (2018-2023) & (K MT)
Table 57. Key Market Drivers & Growth Opportunities of Solid Tumor Drug
Table 58. Key Market Challenges & Risks of Solid Tumor Drug
Table 59. Key Industry Trends of Solid Tumor Drug
Table 60. Solid Tumor Drug Raw Material
Table 61. Key Suppliers of Raw Materials
Table 62. Solid Tumor Drug Distributors List
Table 63. Solid Tumor Drug Customer List
Table 64. Global Solid Tumor Drug Sales Forecast by Region (2024-2029) & (K MT)
Table 65. Global Solid Tumor Drug Revenue Forecast by Region (2024-2029) & ($ millions)
Table 66. Americas Solid Tumor Drug Sales Forecast by Country (2024-2029) & (K MT)
Table 67. Americas Solid Tumor Drug Revenue Forecast by Country (2024-2029) & ($ millions)
Table 68. APAC Solid Tumor Drug Sales Forecast by Region (2024-2029) & (K MT)
Table 69. APAC Solid Tumor Drug Revenue Forecast by Region (2024-2029) & ($ millions)
Table 70. Europe Solid Tumor Drug Sales Forecast by Country (2024-2029) & (K MT)
Table 71. Europe Solid Tumor Drug Revenue Forecast by Country (2024-2029) & ($ millions)
Table 72. Middle East & Africa Solid Tumor Drug Sales Forecast by Country (2024-2029) & (K MT)
Table 73. Middle East & Africa Solid Tumor Drug Revenue Forecast by Country (2024-2029) & ($ millions)
Table 74. Global Solid Tumor Drug Sales Forecast by Type (2024-2029) & (K MT)
Table 75. Global Solid Tumor Drug Revenue Forecast by Type (2024-2029) & ($ Millions)
Table 76. Global Solid Tumor Drug Sales Forecast by Application (2024-2029) & (K MT)
Table 77. Global Solid Tumor Drug Revenue Forecast by Application (2024-2029) & ($ Millions)
Table 78. AstraZeneca Basic Information, Solid Tumor Drug Manufacturing Base, Sales Area and Its Competitors
Table 79. AstraZeneca Solid Tumor Drug Product Portfolios and Specifications
Table 80. AstraZeneca Solid Tumor Drug Sales (K MT), Revenue ($ Million), Price (USD/MT) and Gross Margin (2018-2023)
Table 81. AstraZeneca Main Business
Table 82. AstraZeneca Latest Developments
Table 83. Biogen Basic Information, Solid Tumor Drug Manufacturing Base, Sales Area and Its Competitors
Table 84. Biogen Solid Tumor Drug Product Portfolios and Specifications
Table 85. Biogen Solid Tumor Drug Sales (K MT), Revenue ($ Million), Price (USD/MT) and Gross Margin (2018-2023)
Table 86. Biogen Main Business
Table 87. Biogen Latest Developments
Table 88. Baxter Basic Information, Solid Tumor Drug Manufacturing Base, Sales Area and Its Competitors
Table 89. Baxter Solid Tumor Drug Product Portfolios and Specifications
Table 90. Baxter Solid Tumor Drug Sales (K MT), Revenue ($ Million), Price (USD/MT) and Gross Margin (2018-2023)
Table 91. Baxter Main Business
Table 92. Baxter Latest Developments
Table 93. Celgene Corporation Basic Information, Solid Tumor Drug Manufacturing Base, Sales Area and Its Competitors
Table 94. Celgene Corporation Solid Tumor Drug Product Portfolios and Specifications
Table 95. Celgene Corporation Solid Tumor Drug Sales (K MT), Revenue ($ Million), Price (USD/MT) and Gross Margin (2018-2023)
Table 96. Celgene Corporation Main Business
Table 97. Celgene Corporation Latest Developments
Table 98. Abbott Laboratories Basic Information, Solid Tumor Drug Manufacturing Base, Sales Area and Its Competitors
Table 99. Abbott Laboratories Solid Tumor Drug Product Portfolios and Specifications
Table 100. Abbott Laboratories Solid Tumor Drug Sales (K MT), Revenue ($ Million), Price (USD/MT) and Gross Margin (2018-2023)
Table 101. Abbott Laboratories Main Business
Table 102. Abbott Laboratories Latest Developments
Table 103. Pfizer Inc Basic Information, Solid Tumor Drug Manufacturing Base, Sales Area and Its Competitors
Table 104. Pfizer Inc Solid Tumor Drug Product Portfolios and Specifications
Table 105. Pfizer Inc Solid Tumor Drug Sales (K MT), Revenue ($ Million), Price (USD/MT) and Gross Margin (2018-2023)
Table 106. Pfizer Inc Main Business
Table 107. Pfizer Inc Latest Developments
Table 108. Amgen Limited & Amgen Ireland Limited Basic Information, Solid Tumor Drug Manufacturing Base, Sales Area and Its Competitors
Table 109. Amgen Limited & Amgen Ireland Limited Solid Tumor Drug Product Portfolios and Specifications
Table 110. Amgen Limited & Amgen Ireland Limited Solid Tumor Drug Sales (K MT), Revenue ($ Million), Price (USD/MT) and Gross Margin (2018-2023)
Table 111. Amgen Limited & Amgen Ireland Limited Main Business
Table 112. Amgen Limited & Amgen Ireland Limited Latest Developments
Table 113. Bristol-Myers Squibb Company Basic Information, Solid Tumor Drug Manufacturing Base, Sales Area and Its Competitors
Table 114. Bristol-Myers Squibb Company Solid Tumor Drug Product Portfolios and Specifications
Table 115. Bristol-Myers Squibb Company Solid Tumor Drug Sales (K MT), Revenue ($ Million), Price (USD/MT) and Gross Margin (2018-2023)
Table 116. Bristol-Myers Squibb Company Main Business
Table 117. Bristol-Myers Squibb Company Latest Developments
Table 118. GlaxoSmithKline plc. Basic Information, Solid Tumor Drug Manufacturing Base, Sales Area and Its Competitors
Table 119. GlaxoSmithKline plc. Solid Tumor Drug Product Portfolios and Specifications
Table 120. GlaxoSmithKline plc. Solid Tumor Drug Sales (K MT), Revenue ($ Million), Price (USD/MT) and Gross Margin (2018-2023)
Table 121. GlaxoSmithKline plc. Main Business
Table 122. GlaxoSmithKline plc. Latest Developments
Table 123. F. Hoffmann-La Roche Ltd. Basic Information, Solid Tumor Drug Manufacturing Base, Sales Area and Its Competitors
Table 124. F. Hoffmann-La Roche Ltd. Solid Tumor Drug Product Portfolios and Specifications
Table 125. F. Hoffmann-La Roche Ltd. Solid Tumor Drug Sales (K MT), Revenue ($ Million), Price (USD/MT) and Gross Margin (2018-2023)
Table 126. F. Hoffmann-La Roche Ltd. Main Business
Table 127. F. Hoffmann-La Roche Ltd. Latest Developments
Table 128. Eli Lilly and Company Basic Information, Solid Tumor Drug Manufacturing Base, Sales Area and Its Competitors
Table 129. Eli Lilly and Company Solid Tumor Drug Product Portfolios and Specifications
Table 130. Eli Lilly and Company Solid Tumor Drug Sales (K MT), Revenue ($ Million), Price (USD/MT) and Gross Margin (2018-2023)
Table 131. Eli Lilly and Company Main Business
Table 132. Eli Lilly and Company Latest Developments
Table 133. Johnson & Johnson Basic Information, Solid Tumor Drug Manufacturing Base, Sales Area and Its Competitors
Table 134. Johnson & Johnson Solid Tumor Drug Product Portfolios and Specifications
Table 135. Johnson & Johnson Solid Tumor Drug Sales (K MT), Revenue ($ Million), Price (USD/MT) and Gross Margin (2018-2023)
Table 136. Johnson & Johnson Main Business
Table 137. Johnson & Johnson Latest Developments

List Of Figures

LIST OF FIGURES

Figure 1. Picture of Solid Tumor Drug
Figure 2. Solid Tumor Drug Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Solid Tumor Drug Sales Growth Rate 2018-2029 (K MT)
Figure 7. Global Solid Tumor Drug Revenue Growth Rate 2018-2029 ($ Millions)
Figure 8. Solid Tumor Drug Sales by Region (2018, 2022 & 2029) & ($ Millions)
Figure 9. Product Picture of Small Molecules
Figure 10. Product Picture of Biologics
Figure 11. Global Solid Tumor Drug Sales Market Share by Type in 2022
Figure 12. Global Solid Tumor Drug Revenue Market Share by Type (2018-2023)
Figure 13. Solid Tumor Drug Consumed in Oncology
Figure 14. Global Solid Tumor Drug Market: Oncology (2018-2023) & (K MT)
Figure 15. Solid Tumor Drug Consumed in Neurology
Figure 16. Global Solid Tumor Drug Market: Neurology (2018-2023) & (K MT)
Figure 17. Solid Tumor Drug Consumed in Radiology
Figure 18. Global Solid Tumor Drug Market: Radiology (2018-2023) & (K MT)
Figure 19. Solid Tumor Drug Consumed in Others
Figure 20. Global Solid Tumor Drug Market: Others (2018-2023) & (K MT)
Figure 21. Global Solid Tumor Drug Sales Market Share by Application (2022)
Figure 22. Global Solid Tumor Drug Revenue Market Share by Application in 2022
Figure 23. Solid Tumor Drug Sales Market by Company in 2022 (K MT)
Figure 24. Global Solid Tumor Drug Sales Market Share by Company in 2022
Figure 25. Solid Tumor Drug Revenue Market by Company in 2022 ($ Million)
Figure 26. Global Solid Tumor Drug Revenue Market Share by Company in 2022
Figure 27. Global Solid Tumor Drug Sales Market Share by Geographic Region (2018-2023)
Figure 28. Global Solid Tumor Drug Revenue Market Share by Geographic Region in 2022
Figure 29. Americas Solid Tumor Drug Sales 2018-2023 (K MT)
Figure 30. Americas Solid Tumor Drug Revenue 2018-2023 ($ Millions)
Figure 31. APAC Solid Tumor Drug Sales 2018-2023 (K MT)
Figure 32. APAC Solid Tumor Drug Revenue 2018-2023 ($ Millions)
Figure 33. Europe Solid Tumor Drug Sales 2018-2023 (K MT)
Figure 34. Europe Solid Tumor Drug Revenue 2018-2023 ($ Millions)
Figure 35. Middle East & Africa Solid Tumor Drug Sales 2018-2023 (K MT)
Figure 36. Middle East & Africa Solid Tumor Drug Revenue 2018-2023 ($ Millions)
Figure 37. Americas Solid Tumor Drug Sales Market Share by Country in 2022
Figure 38. Americas Solid Tumor Drug Revenue Market Share by Country in 2022
Figure 39. Americas Solid Tumor Drug Sales Market Share by Type (2018-2023)
Figure 40. Americas Solid Tumor Drug Sales Market Share by Application (2018-2023)
Figure 41. United States Solid Tumor Drug Revenue Growth 2018-2023 ($ Millions)
Figure 42. Canada Solid Tumor Drug Revenue Growth 2018-2023 ($ Millions)
Figure 43. Mexico Solid Tumor Drug Revenue Growth 2018-2023 ($ Millions)
Figure 44. Brazil Solid Tumor Drug Revenue Growth 2018-2023 ($ Millions)
Figure 45. APAC Solid Tumor Drug Sales Market Share by Region in 2022
Figure 46. APAC Solid Tumor Drug Revenue Market Share by Regions in 2022
Figure 47. APAC Solid Tumor Drug Sales Market Share by Type (2018-2023)
Figure 48. APAC Solid Tumor Drug Sales Market Share by Application (2018-2023)
Figure 49. China Solid Tumor Drug Revenue Growth 2018-2023 ($ Millions)
Figure 50. Japan Solid Tumor Drug Revenue Growth 2018-2023 ($ Millions)
Figure 51. South Korea Solid Tumor Drug Revenue Growth 2018-2023 ($ Millions)
Figure 52. Southeast Asia Solid Tumor Drug Revenue Growth 2018-2023 ($ Millions)
Figure 53. India Solid Tumor Drug Revenue Growth 2018-2023 ($ Millions)
Figure 54. Australia Solid Tumor Drug Revenue Growth 2018-2023 ($ Millions)
Figure 55. China Taiwan Solid Tumor Drug Revenue Growth 2018-2023 ($ Millions)
Figure 56. Europe Solid Tumor Drug Sales Market Share by Country in 2022
Figure 57. Europe Solid Tumor Drug Revenue Market Share by Country in 2022
Figure 58. Europe Solid Tumor Drug Sales Market Share by Type (2018-2023)
Figure 59. Europe Solid Tumor Drug Sales Market Share by Application (2018-2023)
Figure 60. Germany Solid Tumor Drug Revenue Growth 2018-2023 ($ Millions)
Figure 61. France Solid Tumor Drug Revenue Growth 2018-2023 ($ Millions)
Figure 62. UK Solid Tumor Drug Revenue Growth 2018-2023 ($ Millions)
Figure 63. Italy Solid Tumor Drug Revenue Growth 2018-2023 ($ Millions)
Figure 64. Russia Solid Tumor Drug Revenue Growth 2018-2023 ($ Millions)
Figure 65. Middle East & Africa Solid Tumor Drug Sales Market Share by Country in 2022
Figure 66. Middle East & Africa Solid Tumor Drug Revenue Market Share by Country in 2022
Figure 67. Middle East & Africa Solid Tumor Drug Sales Market Share by Type (2018-2023)
Figure 68. Middle East & Africa Solid Tumor Drug Sales Market Share by Application (2018-2023)
Figure 69. Egypt Solid Tumor Drug Revenue Growth 2018-2023 ($ Millions)
Figure 70. South Africa Solid Tumor Drug Revenue Growth 2018-2023 ($ Millions)
Figure 71. Israel Solid Tumor Drug Revenue Growth 2018-2023 ($ Millions)
Figure 72. Turkey Solid Tumor Drug Revenue Growth 2018-2023 ($ Millions)
Figure 73. GCC Country Solid Tumor Drug Revenue Growth 2018-2023 ($ Millions)
Figure 74. Manufacturing Cost Structure Analysis of Solid Tumor Drug in 2022
Figure 75. Manufacturing Process Analysis of Solid Tumor Drug
Figure 76. Industry Chain Structure of Solid Tumor Drug
Figure 77. Channels of Distribution
Figure 78. Global Solid Tumor Drug Sales Market Forecast by Region (2024-2029)
Figure 79. Global Solid Tumor Drug Revenue Market Share Forecast by Region (2024-2029)
Figure 80. Global Solid Tumor Drug Sales Market Share Forecast by Type (2024-2029)
Figure 81. Global Solid Tumor Drug Revenue Market Share Forecast by Type (2024-2029)
Figure 82. Global Solid Tumor Drug Sales Market Share Forecast by Application (2024-2029)
Figure 83. Global Solid Tumor Drug Revenue Market Share Forecast by Application (2024-2029)